Cyclophosphamide leads to persistent deficits in physical performance and in vivo mitochondria function in a mouse model of chemotherapy late effects

• Published in: PloS one 2017-07, Vol.12 (7), p.e0181086
• Main Authors: Crouch, Marie-Laure, Knowels, Gary, Stuppard, Rudolph, Ericson, Nolan G, Bielas, Jason H, Marcinek, David J, Syrjala, Karen L
• Format: Article
• Language: English
• Subjects: Adducts; Animals; ATP; Biology and Life Sciences; Blotting, Western; Breast cancer; Cancer; Cancer therapies; Care and treatment; Catalase; Chemotherapy; Citrate (si)-Synthase - metabolism; Cyclophosphamide; Cyclophosphamide - pharmacology; Deoxyribonucleic acid; DNA; DNA, Mitochondrial - genetics; Dosage and administration; Drug dosages; Exposure; Fatigue; Female; Health aspects; Health sciences; Heart diseases; Immunoblotting; Medical research; Medicine; Medicine and Health Sciences; Metabolism; Methods; Mice; Mice, Inbred C57BL; Mitochondria; Mitochondria - drug effects; Mitochondria - metabolism; Mitochondrial DNA; Muscle, Skeletal - drug effects; Muscle, Skeletal - metabolism; Muscles; Musculoskeletal system; Mutation; Oxidative stress; Patient outcomes; Phosphocreatine; Public health; Quantitation; Research and Analysis Methods; Running; Sarcopenia; Skeletal muscle; Synaptotagmin; Toxicity
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0181086

Fatigue is the symptom most commonly reported by long-term cancer survivors and is increasingly recognized as related to skeletal muscle dysfunction. Traditional chemotherapeutic agents can cause acute toxicities including cardiac and skeletal myopathies. To investigate the mechanism by which chemotherapy may lead to persistent skeletal muscle dysfunction, mature adult mice were injected with a single cyclophosphamide dose and evaluated for 6 weeks. We found that exposed mice developed a persistent decrease in treadmill running time compared to baseline (25.7±10.6 vs. 49.0±16.8 min, P = 0.0012). Further, 6 weeks after drug exposure, in vivo parameters of mitochondrial function remained below baseline including maximum ATP production (482.1 ± 48.6 vs. 696.2 ± 76.6, P = 0.029) and phosphocreatine to ATP ratio (3.243 ± 0.1 vs. 3.878 ± 0.1, P = 0.004). Immunoblotting of homogenized muscles from treated animals demonstrated a transient increase in HNE adducts 1 week after exposure that resolved by 6 weeks. However, there was no evidence of an oxidative stress response as measured by quantitation of SOD1, SOD2, and catalase protein levels. Examination of mtDNA demonstrated that the mutation frequency remained comparable between control and treated groups. Interestingly, there was evidence of a transient increase in NF-ĸB p65 protein 1 day after drug exposure as compared to saline controls (0.091±0.017 vs. 0.053±0.022, P = 0.033). These data suggest that continued impairment in muscle and mitochondria function in cyclophosphamide-treated animals is not linked to persistent oxidative stress and that alternative mechanisms need to be considered.